A Phase 1b/2a, Safety, Pharmacokinetic and Dose-Escalation Study of KD019 in Subjects With Autosomal Dominant Polycystic Kidney Disease

Trial Profile

A Phase 1b/2a, Safety, Pharmacokinetic and Dose-Escalation Study of KD019 in Subjects With Autosomal Dominant Polycystic Kidney Disease

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 17 Aug 2017

At a glance

  • Drugs Tesevatinib (Primary)
  • Indications Autosomal dominant polycystic kidney disease
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Sponsors Kadmon Corporation
  • Most Recent Events

    • 03 Feb 2017 Status changed from recruiting to active, no longer recruiting.
    • 19 Nov 2016 According to a Kadmon Corporation media release, data from the study will be presented in a poster session at the American Society of Nephrology (ASN) Kidney Week 2016.
    • 19 Nov 2016 Results published in a Kadmon Corporation media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top